La Jolla Pharmaceutical Company (NASDAQ:LJPC) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 11, 2016
Zacks Investment Research has downgraded La Jolla Pharmaceutical Company (NASDAQ:LJPC) to Sell in a statement released on 10/12/2016.
Having a price of $22.19, La Jolla Pharmaceutical Company (NASDAQ:LJPC) traded -3.48% lower on the day. With the last stock price up 18.86% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. LJPC has recorded a 50-day average of $21.42 and a two hundred day average of $18.67. Trade Volume was down over the average, with 94,232 shares of LJPC changing hands under the typical 120,552
Recent Performance Chart
La Jolla Pharmaceutical Company has with a one year low of $12.68 and a one year high of $35.95 and has a market capitalization of $0.
A total of 5 brokerages have released a report on La Jolla Pharmaceutical Company. One brokerage rating the company a strong buy, four brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $42.00.
General Company Details For La Jolla Pharmaceutical Company (NASDAQ:LJPC)
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.